Compared to low dose groups, RRs for any grade pruritus and any grade rash developed after high dose PD-1/PD-L1 inhibitor therapy were 0.84 (95%CI 0.63-1.14, p = 0.26) (Supplementary Figure 4A) and 0.79 (95%CI 0.56-1.11, p = 0.17) respectively (Supplementary Figure 4B). This evidence concerns the gene CD274 and Pruritus.